Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 14/20 | 0.80 |
| ▸ | KIT | P10721 | 7/20 | 0.80 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.80 |
| ▸ | JAK2 | O60674 | 2/20 | 0.80 |
| ▸ | AURKA | O14965 | 2/20 | 0.80 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.57 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037104 | 0.89 | AXL (0.79) | AXLFLT3KITIRAK4JAK2 | |
| SCHEMBL4039212 | 0.89 | FLT3 (1.00) | AXLFLT3KITIRAK4JAK2 | |
| SCHEMBL13963540 | 0.88 | AXL (0.78) | AXLFLT3KITIRAK4JAK2 | |
| SCHEMBL4040306 | 0.86 | AXL (0.76) | AXLFLT3KITIRAK4JAK2 | |
| SCHEMBL4038800 | 0.85 | AXL (0.74) | AXLFLT3KITIRAK4JAK2 | |
| SCHEMBL4045096 | 0.85 | AXL (0.72) | AXLFLT3KITIRAK4JAK2 | |
| SCHEMBL4038216 | 0.84 | AXL (0.73) | AXLFLT3KITIRAK4JAK2 | |
| SCHEMBL12779847 | 0.84 | AXL (0.71) | AXLFLT3KITIRAK4JAK2 | |
| SCHEMBL4038067 | 0.84 | FLT3 (0.86) | AXLFLT3KITIRAK4JAK2 | |
| SCHEMBL4040900 | 0.84 | FLT3 (0.82) | AXLFLT3KITIRAK4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | claimed |
| CN-110551105-B | Substituted triazoles useful as AXL inhibitors | 里格尔制药公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-110551105-A | substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2019-12-10 | — | — | CN | disclosed |
| US-10166216-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-08-25 | — | — | US | disclosed |
| US-9353126-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150072959-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2015-03-12 | — | — | US | disclosed |
| US-8906922-B2 | Substituted triazoles useful as AXl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2476679-A2 | Substituted triazoles useful as AXL inhibitors | Rigel Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166216-B2 | Substituted triazoles useful as Axl inhibitors | AXL, TYRO3, MERTK | AXL 1/4885FLT3 4/4885KIT 383/4885 |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | AXL 762/4885FLT3 220/4885KIT 1144/4885 |
| US-20150072959-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | AXL 1/4885FLT3 4/4885KIT 383/4885 |
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | AXL 1/4885FLT3 4/4885KIT 383/4885 |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | AXL, TYRO3, FLT3 | AXL 1/4885FLT3 3/4885KIT 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.